ADAR1 Capital Management LLC bought a new position in shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,341,394 shares of the company's stock, valued at approximately $6,144,000. ADAR1 Capital Management LLC owned approximately 2.35% of Whitehawk Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors also recently bought and sold shares of the company. Quadrature Capital Ltd acquired a new stake in Whitehawk Therapeutics in the 4th quarter valued at about $28,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Whitehawk Therapeutics in the first quarter valued at approximately $40,000. Dimensional Fund Advisors LP acquired a new stake in shares of Whitehawk Therapeutics in the third quarter valued at approximately $84,000. Deutsche Bank AG purchased a new position in shares of Whitehawk Therapeutics during the 2nd quarter worth approximately $145,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Whitehawk Therapeutics during the 3rd quarter worth approximately $159,000. Institutional investors and hedge funds own 52.08% of the company's stock.
Whitehawk Therapeutics Stock Performance
Shares of WHWK opened at $5.08 on Wednesday. Whitehawk Therapeutics, Inc. has a fifty-two week low of $1.71 and a fifty-two week high of $5.49. The company has a market capitalization of $289.61 million, a PE ratio of -4.54 and a beta of 0.76. The stock has a fifty day moving average of $4.24 and a two-hundred day moving average of $3.95.
Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.10. As a group, equities research analysts forecast that Whitehawk Therapeutics, Inc. will post -1.1 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of brokerages have commented on WHWK. Wall Street Zen upgraded Whitehawk Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Weiss Ratings cut Whitehawk Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a report on Friday, June 5th. Leerink Partners started coverage on Whitehawk Therapeutics in a research report on Monday, July 13th. They issued an "outperform" rating and a $9.00 price objective on the stock. Oppenheimer reaffirmed an "outperform" rating and set a $7.00 price objective on shares of Whitehawk Therapeutics in a research note on Friday, May 8th. Finally, B. Riley Financial assumed coverage on Whitehawk Therapeutics in a research report on Thursday, June 25th. They set a "buy" rating and a $10.00 price objective for the company. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $8.20.
Get Our Latest Stock Report on Whitehawk Therapeutics
About Whitehawk Therapeutics
(
Free Report)
Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Featured Stories
Want to see what other hedge funds are holding WHWK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Whitehawk Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Whitehawk Therapeutics wasn't on the list.
While Whitehawk Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
